Ultragenyx Pharmaceutical (RARE) Set to Post Quarterly Earnings on Tuesday

Ultragenyx Pharmaceutical (NASDAQ:RARE) is expected to be posting its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to announce earnings of ($1.10) per share and revenue of $182.49 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 5:00 PM ET.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, topping the consensus estimate of ($1.22) by $0.32. The business had revenue of $214.00 million during the quarter, compared to analysts’ expectations of $183.08 million. During the same period in the previous year, the company posted ($1.17) EPS. Ultragenyx Pharmaceutical’s revenue for the quarter was up 28.5% on a year-over-year basis. On average, analysts expect Ultragenyx Pharmaceutical to post ($3.91) EPS for the current fiscal year and ($0.27) EPS for the next fiscal year.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE opened at $16.08 on Tuesday. The company has a 50 day moving average price of $17.74 and a 200-day moving average price of $23.03. Ultragenyx Pharmaceutical has a fifty-two week low of $12.73 and a fifty-two week high of $39.89. The stock has a market capitalization of $1.59 billion, a PE ratio of -2.75 and a beta of 0.35.

Wall Street Analysts Forecast Growth

RARE has been the topic of several research reports. Citigroup lifted their price objective on shares of Ultragenyx Pharmaceutical from $31.00 to $32.00 and gave the company a “buy” rating in a report on Friday, September 18th. Royal Bank Of Canada lowered Ultragenyx Pharmaceutical from a “moderate buy” rating to a “hold” rating in a report on Thursday, September 3rd. Evercore cut Ultragenyx Pharmaceutical from an “outperform” rating to an “in-line” rating and set a $16.00 target price on the stock. in a research report on Thursday, September 3rd. Guggenheim cut their price target on Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday, August 4th. Finally, Cantor Fitzgerald lifted their price target on Ultragenyx Pharmaceutical from $33.00 to $39.00 and gave the company an “overweight” rating in a report on Friday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical presently has a consensus rating of “Hold” and a consensus price target of $33.65.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,066 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $15.27, for a total value of $107,897.82. Following the completion of the sale, the chief financial officer directly owned 89,229 shares in the company, valued at $1,362,526.83. This trade represents a 7.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 8,510 shares of company stock valued at $127,561 in the last three months. 5.20% of the stock is owned by company insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.